{
  "url": "https://www.law.cornell.edu/regulations/new-york/8-NYCRR-63.10",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 8 ยง 63.10 - Collaborative drug therapy management",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 8 ยง 63.10 - Collaborative drug therapy management\n\nState Regulations\n(a) Applicability. This section shall apply only to the extent that the\napplicable provisions in Education Law sections 6801 and 6801-a, authorizing\ncertain pharmacists to participate in collaborative drug therapy management, have not expired or been repealed. (b) Definitions. As used in this section: (1)\n\nBoard\nmeans the State\n\nBoard of Pharmacy as established by section\n6804\nof the\n\nEducation Law. (2)\n\nClinical\nservices\nmeans the collection and interpretation of patient data for\nthe purpose of initiating, modifying and monitoring drug therapy with\nassociated accountability and responsibility for outcomes in a direct patient\ncare setting. (3)\n\nCollaborative drug therapy management\nmeans the performance of\nclinical services by a pharmacist relating to the review, evaluation and\nmanagement of drug therapy to a patient, who is being treated by a physician\nfor a specific disease or associated disease states, in accordance with a\nwritten agreement or protocol with a voluntarily participating physician and in\naccordance with the policies, procedures, and protocols of the\nfacility. (4)\n\nFacility\nmeans: (i) a\nteaching hospital or general hospital, including any diagnostic center, treatment center, or hospital-based out-patient department as defined in\nsection\n2801\nof the\n\nPublic Health Law; or\n(ii)\na\nnursing home with an on-site pharmacy staffed by a licensed pharmacist; provided, however, for the purposes of this section the term facility shall not\ninclude dental clinics, dental dispensaries, residential health care facilities\nand rehabilitation centers. (5)\n\nTeaching hospital\nmeans\na hospital licensed pursuant to article 28 of the Public Health Law that is\neligible to receive direct or indirect graduate medical education payments\npursuant to article 28 of the Public Health Law. (6)\n\nPhysician\nmeans the\nphysician selected by or assigned to a patient, who has primary responsibility\nfor the treatment and care of the patient for the disease and associated\ndisease states that are the subject of the collaborative drug therapy\nmanagement. (7)\n\nWritten\nagreement\nor\nprotocol\nmeans a written document, pursuant to and consistent with an applicable State or Federal requirements, that addresses a specific disease or associated disease states and that\ndescribes the nature and scope of collaborative drug therapy management to be\nundertaken by the pharmacists, in collaboration with the participating\nphysician in accordance with the requirements of this section. (c) Requirements. A pharmacist seeking to engage in collaborative drug\ntherapy management shall submit his or her credentials, in a form determined by\nthe department, to the department for review. Those pharmacists who the\ndepartment determines to meet the requirements of paragraph (3) of this\nsubdivision and who are employed by or otherwise affiliated with a facility\nshall be permitted to enter into a written agreement or protocol with a\nphysician authorizing collaborative drug therapy management, subject to the\nlimitations set forth in this section, within the scope of such employment or\naffiliation, and shall be identified as being so authorized by a designation\ndetermined by the department. (1)\n\nAs\nused in section\n6801-a\n(2)(b)\nof the Education Law, a year\nof experience\nshall mean not less than 1,680 hours of work as a\npharmacist within a period of one calendar year. (2)\n\nIn order to be counted as a year of\nexperience that includes clinical experience in a health facility, such\nexperience shall include, on average, not less than 15 hours per week of\nclinical experience which involves consultation with physicians with respect to\ndrug therapy, as determined by the facility with which the pharmacist is\nemployed or affiliated. (3)\nA\nparticipating pharmacist shall: (i) (a) have been awarded either a master of\nscience in clinical pharmacy or a doctor of pharmacy degree; (b) maintain a current unrestricted license; and\n(c) have a minimum of two\nyears' experience, of which at least one year of such experience shall include\nclinical experience in a health facility, which involves consultation with\nphysicians with respect to drug therapy and may include a residency at a\nfacility involving such consultation, and such clinical experience shall be\ngained within the three years immediately preceding the pharmacist' submission\nof his or her credentials to the department for review; or\n(ii)\n(a) have been awarded a bachelor of science in pharmacy; (b) maintain a current unrestricted license; and\n(c) within the last seven\nyears, have a minimum of three years' experience, of which at least one year of\nsuch experience shall include clinical experience in a health facility, which\ninvolves consultation with physicians with respect to drug therapy and may\ninclude a residency at a facility involving such consultation, and such\nclinical experience shall be gained within the three years immediately\npreceding the pharmacist' submission of his or her credentials to the\ndepartment for review; and\n(iii)\n(a) have residency training in a program accredited or accreditation-pending by a\nnationally recognized accreditation body acceptable the department; or\n(b) have board certification\nawarded by a certification body acceptable to the department and shall include\nbaseline and ongoing competency assessments; and\n(iv)\nmeet additional experience provisions as\nfollows: (a) for pharmacists seeking to engage\nin collaborative drug therapy management by satisfying the requirements of\nclauses (i)(\na\n) though (\nc\n) of this paragraph, if he or she seeks to utilize residency training to satisfy the one year of\nclinical experience requirement, the second year of required experience shall\nalso be clinical experience, unless such pharmacist possesses board\ncertification that satisfies the requirements of clause\n(iii)(\nb\n) of this paragraph. (b) for pharmacists seeking to engage in\ncollaborative drug therapy by satisfying the requirements of clauses\n(ii)(\na\n) through (\nc\n) of this paragraph, if he\nor she seeks to utilize residency training to satisfy the one year of clinical\nexperience requirement, an additional year' experience of the three years\nrequired shall also be clinical experience, unless such pharmacist possesses\nboard certification that satisfies the requirements of clause\n(iii)(\nb\n) of this paragraph. (d) Requirements for\ncollaborative drug therapy management written agreements or protocols. A physician who is a party to a written agreement or\nprotocol to authorize collaborative drug treatment shall be employed by or\notherwise affiliated with the same facility with which the pharmacist is also\nemployed or affiliated and their written agreement or protocol may include, and\nshall be limited to, the following: (1)\nadjusting or managing a drug regimen of a patient, pursuant to a patient\nspecific order or protocol made by the patient' physician, which may include\nadjusting drug strength, frequency of administration or route of\nadministration. Adjusting the drug regimen shall not include substituting or\nselecting a different drug which differs from that initially prescribed by the\npatient' physician unless such substitution is expressly authorized in the\nwritten order or protocol. The pharmacist shall be required to immediately\ndocument in the patient' medical record changes made to the patient's drug\ntherapy and shall use any reasonable means or method established by the\nfacility to notify the patient's other treating physicians with whom he or she\ndoes not have a written agreement or protocol regarding such changes. The\npatient's physician may prohibit, by written instruction, any adjustment or\nchange in the patient's drug regiment by the pharmacist; (2)\nevaluating and, only if specifically\nauthorized by the protocol and only to the extent necessary to discharge the\nresponsibilities set forth in this section, ordering disease State laboratory\ntests related to the drug therapy management for the specific disease or\ndisease state specified within the written agreement or protocol; and\n(3)\nonly if specifically authorized by the\nwritten agreement or protocol and only to the extent necessary to discharge the\nresponsibilities set forth in this section, ordering or performing routine\npatient monitoring functions as may be necessary in the drug therapy\nmanagement, including the collecting and reviewing of patient histories, and\nordering or checking patient vital signs, including pulse, temperature, blood\npressure and respiration. (e) Additional provisions relating to\ncollaborative drug therapy management written agreements and protocols. (1)\n\nThe existence of a written agreement or\nprotocol on collaborative drug therapy management and the patient's right to\nchoose to not participate in collaborative drug therapy management shall be\ndisclosed to any patient who is eligible to receive collaborative drug therapy\nmanagement. Collaborative drug therapy management shall not be utilized unless\nthe patient or the patient's authorized representative consents, in writing, to\nsuch management. If the patient or the patient's authorized representative\nconsents, it shall be noted on the patient's medical record. If the patient or\nthe patient's authorized representative who consented to collaborative drug\ntherapy management chooses to no longer participate in such management, at any\ntime, it shall be noted in the patient's medical record. In addition, the\nexistence of the written agreement or protocol and the patient's consent to\nsuch management shall be disclosed to the patient's primary care physician and\nany other treating physician or healthcare provider. (2)\n\nParticipation in a written agreement or\nprotocol authorizing collaborative drug therapy management shall be voluntary, and no patient, physician, pharmacist, or facility shall be required to\nparticipate. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 8\nยง\n63.10\n\nAmended\n\nNew\n\nYork State Register March 9, 2016/Volume XXXVIII, Issue 10, eff. 3/9/2016\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. No prior version found.",
  "url_type": "regulation",
  "source_index": 32639
}